By Pat Anson, Editor
An FDA decision to block a generic version of OxyContin from coming on the market is a “clear mandate” that other opioid painkillers will have to be made tamper resistant, according to the head of the German pharmaceutical company that developed the technology that makes it harder for pills to be crushed and abused.
“My personal view is this is a precedent on how the FDA will move on other (drug) molecules,” Harald Stock, CEO of Grunenthal Group, told the National Pain Report. Grunenthal licensed its abuse-deterrent technology to Purdue Pharma, which began using it in OxyContin in 2010.
On Tuesday, the Food and Drug Administration approved new labeling for OxyContin stating that the reformulated version of the painkiller is harder to crush or dissolve and reduces chances of abuse. It’s the first time the FDA has recognized the effectiveness of a tamper-resistant product.
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
August 20, 2016
August 19, 2016
August 18, 2016
Since the cannabis industry is still so new and growing, I can see why
Really good info. Thanks!
Charity is just writing checks and not being engaged. Philanthropy, to
This is the most insane thing I have ever heard of. Good grief -- the
In the opener, Scott carried the ball six times on an eight-play drive